Manual
Description
The antimicrobial protein BPI (Bactericidal Permeability Increasing protein) is a 55 kDa protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells. BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils. BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane. Binding of BPI to the lipid A moiety of LPS exerts multiple anti-infective activities against gram-negative bacteria: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. Airway epithelial cells constitutively express the BPI gene and produce the BPI protein and, therefore, BPI may be a critical determinant in the development of LPS-triggered airway disease. Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation. Furthermore, a 21 kDa bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage against invasive pneumococcal disease by binding to the gram-positive bacterial pathogen, pneumolysin. In plasma of healthy individuals BPI is present at levels of < 0.5 ng/ml, which increases approximately 10-fold during acute phase responses.
Application
The human BPI ELISA kit has been developed for the quantitative measurement of natural and recombinant human BPI in culture medium, plasma, wound fluid and broncheoalveolar lavage fluid. In plasma samples human BPI can be measured accurately if plasma samples are diluted at least 4 times. Most reliable results are obtained if EDTA plasma is used. Please be aware that BPI is released from neutrophils into serum in the process of blood coagulation. This will lead to false positive and difficult to interpret results of serum samples. Therefore it is advised to use 'careful plasma'.
Features
- Minimum concentration which can be measured is 250 pg/ml human BPI.
- Measurable concentration range of 100-25,000 pg/ml.
- Working volume of 100 µl/well.
Typical standard curve
Principle
- The human BPI ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 4½ hours.
- The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay.
- Samples and standards are captured by a solid bound specific antibody.
- Biotinylated tracer antibody will bind to captured human BPI.
- Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody.
- Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB).
- The enzyme reaction is stopped by the addition of citric acid.
- The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human BPI standards (log).
- The human BPI concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least six months. After reconstitution the reagents are stable for 1 month if stored at 2-8°C. After reconstitution the standard is stable for 24 hours. For longer stability we recommend to store aliquots at -20°C. Stored at -20°C the standard will be stable for 7 days.
References
- Espinoza, J et al; Antimicrobial peptides in amniotic fluid: defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes. J Matern Fetal Neonatal Med 2003, 13: 2
- Gubern, C et al; Natural antibiotics and insulin sensitivity. The role of bactericidal/Permeability-Increasing protein. Diabetes 2006, 55:216
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product.
Also available